PL EN


Preferences help
enabled [disable] Abstract
Number of results
2000 | 48 | 3 | 183-188
Article title

Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648

Authors
Title variants
Languages of publication
EN
Abstracts
EN
In this article, I have thoroughly reviewed the status of development of new antimycobacterial drugs, in particular, rifamycin derivatives (rifabutin, rifapentine, and a new benzoxazinorifamycin, KRM-1648), fluoroquinolones (ciprofloxacin, ofloxacin, sparfloxacin, levofloxacin, gatifloxacin, sitafloxacin, moxifloxacin, and others), new macrolides (clarithromycin, azithromycin, roxithromycin), and others. In this review, I have mainly described the in vitro and in vivo activities of these drugs against Mycobacterium tuberculosis and atypical mycobacteria, especially Mycobacterium avium complex. In addition, therapeutic efficacy of these drugs in cases of clinical treatment of mycobacterial infections have also been briefly mentioned.
Contributors
author
References
Document Type
REVIEW
Publication order reference
H.Tomioka, Department of Microbiology and Immunology, Shimane Medical University, Izumo, Shimane 693-8501, Japan
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-7ec71213-7e58-3030-a42a-b8876cf9b51e
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.